Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma

• DOI: 10.2147/ott.s132756
• Publication Date: 2017-08-08T01:30:25Z
• Authors: Jianqiang Li; Lifen Wang
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Oncology; Pharmacology (medical); OncoTargets and Therapy; Original Research; 3. Good health

No standard chemotherapy is available for patients with advanced esophageal squamous cell carcinoma (ESCC) who have failed prior first-line chemotherapy. The aim of this study was to evaluate the efficacy and safety of apatinib, an oral VEGFR-2 inhibitor, as salvage treatment for advanced ESCC.After apatinib dosing, the efficacy and toxicity were evaluated in 62 patients with pretreated advanced ESCC from 2014 to 2016 at Zhejiang Cancer Hospital. In addition, survival analysis was performed by the Kaplan-Meier method.Among the 62 patients, 15 achieved partial response while 31 had stable disease with a response rate of 24.2% and a disease control rate of 74.2%. Median progression-free survival (PFS) and overall survival were 115 and 209 days, respectively. Grade 3/4 toxicities (59.7%) were acceptable. Patients with grade 3/4 toxicities showed a longer PFS than those without (136 vs 63 days, P=0.044).Apatinib is efficacious as second- or further-line treatment for advanced ESCC.